215 related articles for article (PubMed ID: 31303142)
1. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting.
Casado JL; Monsalvo M; Fontecha M; Vizcarra P; Rodriguez MA; Vivancos MJ; Moreno S
HIV Res Clin Pract; 2019 Apr; 20(2):64-72. PubMed ID: 31303142
[No Abstract] [Full Text] [Related]
2. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
Palacios R; Mayorga M; González-Domenech CM; Hidalgo-Tenorio C; Gálvez C; Muñoz-Medina L; de la Torre J; Lozano A; Castaño M; Omar M; Santos J
J Int Assoc Provid AIDS Care; 2018; 17():2325958218760847. PubMed ID: 29529910
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
[TBL] [Abstract][Full Text] [Related]
5. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
van Wyk J; Orkin C; Rubio R; Bogner J; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Matthews J; Wang R; Underwood M; Wynne B; Nascimento MC; Vandermeulen K; Gartland M; Smith KY
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):325-330. PubMed ID: 32675772
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients.
Riccardi N; Del Puente F; Taramasso L; Di Biagio A
J Int Assoc Provid AIDS Care; 2019; 18():2325958218821657. PubMed ID: 30798670
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.
Merli M; Galli L; Marinaro L; Ariaudo A; Messina E; Uberti-Foppa C; Castagna A; D'Avolio A; Lazzarin A; Bonora S; Hasson H
J Antimicrob Chemother; 2017 Mar; 72(3):812-815. PubMed ID: 27999010
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.
Capetti AF; Cossu MV; Sterrantino G; Barbarini G; Di Giambenedetto S; De Socio GV; Orofino G; Di Biagio A; Celesia BM; Rusconi S; Argenteri B; Rizzardini G
Ann Pharmacother; 2018 Aug; 52(8):740-746. PubMed ID: 29482352
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
Hester EK; Astle K
Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
[No Abstract] [Full Text] [Related]
11. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
Ribera E
AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
[TBL] [Abstract][Full Text] [Related]
12. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
Ramos-Ruperto L; Arcos-Rueda MDM; de Miguel-Buckley R; Busca-Arenzana C; Mican R; Montejano R; Delgado-Hierro A; Montes ML; Valencia ME; Serrano L; Arribas JR; González J; Bernardino JI; Martín-Carbonero L
HIV Med; 2024 Jun; 25(6):684-691. PubMed ID: 38379338
[TBL] [Abstract][Full Text] [Related]
13. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
15. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J; Ryan P; Ribera E; Podzamczer D; Hontañón V; Terrón JA; Boix V; Moreno S; Barrufet P; Castaño M; Carrero A; Galindo MJ; Suárez-Lozano I; Knobel H; Raffo M; Solís J; Yllescas M; Esteban H; González-García J; Berenguer J; Imaz A;
PLoS One; 2016; 11(10):e0164455. PubMed ID: 27727331
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Lagi F; Giacomelli A; Borghi V; Ciccullo A; Taramasso L; Madeddu G; D'Ettorre G; Giacometti A; Ducci F; De Vito A; Pincino R; Di Giambenedetto S; Mussini C; Antinori S; Sterrantino G
J Med Virol; 2023 Oct; 95(10):e29149. PubMed ID: 37805832
[TBL] [Abstract][Full Text] [Related]
20. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
